Antiphospholipid syndrome, thrombosis, and vaccination in the COVID-19 pandemic

Area of Science:

• Immunology
• Hematology
• Infectious Diseases

Background:

• Thrombosis is a key feature of both antiphospholipid syndrome (APS) and COVID-19.
• The precise mechanisms linking APS and COVID-19-associated thrombosis are still under investigation.
• The co-occurrence of APS and COVID-19 presents diagnostic and management challenges.

Purpose of the Study:

• To review the interplay between antiphospholipid antibodies (aPLs), APS, COVID-19, and thrombosis.
• To discuss diagnostic insights regarding aPLs in the context of COVID-19.
• To evaluate the safety and tolerability of COVID-19 vaccination in APS patients.

Main Methods:

• Narrative review of existing literature.
• Analysis of studies on aPL prevalence in COVID-19 patients.
• Examination of data on thrombosis and thrombocytopenia in APS and post-vaccination.

Main Results:

• Antiphospholipid antibodies (aPLs) are prevalent in severe COVID-19 but not consistently associated with thrombosis or adverse outcomes.
• Thrombosis and thrombocytopenia are rare but recognized complications of mRNA COVID-19 vaccination.
• COVID-19 vaccination appears safe and well-tolerated in APS patients, including those with triple-positive aPL status.

Conclusions:

• Monitoring aPL positivity over time is crucial for APS diagnosis.
• COVID-19 vaccination may alleviate concerns for APS/aPL-positive individuals regarding immunization.
• Further research is needed to fully elucidate the complex interactions between aPLs, APS, COVID-19, and thrombosis.